Hypothesis

Age‑related decline in the gut bacterium Lactonifactor reduces equol production, weakening ERβ‑AMPK signaling and permitting mTORC1 hyperactivation, which shifts cells from a cooperative, tissue‑level state to a solitary survival mode.

Mechanistic Rationale

Equol acts as a selective ERβ agonist (6). ERβ activation can stimulate AMPK phosphorylation through upstream kinases such as LKB1, a pathway well‑established in metabolic tissues (2). Activated AMPK phosphorylates TSC2 and Raptor, inhibiting mTORC1 activity and promoting autophagy (1). Longitudinal data show that stable equol producers harbor greater microbial diversity and enrichment of saccharolytic/butyrogenic taxa (4), suggesting a conserved network that includes Lactonifactor as a keystone contributor to daidzein conversion. When this network deteriorates with age, equol falls, ERβ‑AMPK tone drops, and mTORC1-driven anabolic programs prevail, fostering senescence and compromised proteostasis.

Testable Predictions

1. Oral gavage of Lactonifactor isolated from young, equol‑positive donors will increase fecal equol and decrease phosphorylated S6K (p‑S6K) in intestinal epithelium and liver of aged mice.
2. The reduction in p‑S6K will be abolished in mice lacking intestinal ERβ (Villin‑Cre;Esr2^fl/fl) or treated with the AMPK inhibitor Compound C.
3. Fecal microbiota transplantation (FMT) from stable equol‑producing human donors into antibiotic‑treated, equol‑negative recipients will lower colonic mTORC1 signaling markers (p‑S6K, p‑4EBP1) within two weeks.
4. Chronic equol supplementation in Lactonifactor-deficient germ‑free mice will rescue AMPK activation and extend healthspan metrics (grip strength, frailty index) only when ERβ is present.

Experimental Approach

• Mouse cohorts: young (3 mo) and aged (18 mo) C57BL/6J mice, subdivided into control, Lactonifactor mono‑association, equol gavage, ERβ‑KO, AMPK‑inhibited, and FMT groups.
• Readouts: fecal equol quantification by LC‑MS, colonic and hepatic p‑S6K/p‑4EBP1 Western blot, AMPK‑Thr172 phosphorylation, autophagy flux (LC3‑II/I, p62), intestinal barrier integrity (FITC‑dextran), and systemic inflammation (IL‑6, TNF‑α).
• Longitudinal arm: track equol producer status and mTORC1 activity in humans over 12 months with intermittent soy‑daidzein challenge; correlate shifts in Lactonifactor relative abundance (16S rRNA sequencing) with changes in peripheral blood p‑S6K in monocytes.
• Statistical plan: power analysis targeting 80 % detection of a 30 % change in p‑S6K; ANOVA with Tukey post‑hoc for multiple groups; mixed‑effects models for human longitudinal data.

Potential Implications

Confirming that a specific gut microbe sustains a molecular bridge from dietary isoflavones to mTORC1 restraint would reframe longevity interventions: rather than blanket rapamycin‑like suppression, fostering Lactonifactor‑dependent equol production could preserve the organism’s "civilizational" functions (tissue coordination, specialized metabolism) while still engaging survival pathways. This hypothesis directly ties microbiome instability to a canonical aging signaling hub, offering a biomarker‑driven, microbiome‑targeted strategy to delay age‑related decline without sacrificing essential anabolic processes.